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Human Phase I and Phase II drug metabolizing enzymes are known to interact 
with foreign chemicals that enter the body as a defense mechanism, however, it is often
the case that unwanted interactions can occur. Phase I metabolism may form reactive 
electrophiles that can covalently modify DNA, proteins and lipids. These modified 
electrophilic biomolecules are thought to cause progression of many diseases such a
Parkinson’s and Alzheimer’s Disease (3). On the other hand, Phase II enzymes can 
remove the toxic compounds of the Phase I enzymes. The Phase II enzymes are likely 
induced via biochemical pathway involving the nuclear transcription factor Nrf2 (4).     
This current study was designed to probe specific interactions between commonly 
used essential oils, along with their major aldehyde constituents, and CYP2A6.  The 
overall goal was to gain a better understanding of factors that may govern the inhibitory 
effects of aldehydes on this isoform. In addition, the ability of the essential oil of Cassia 
and it’s primary constituent, cinnamaldehyde on Phase II gene induction was probed as 
well using cultured human hepatoma cells (HepG2).  Here the goal was to gain a better
understanding of the relationship between oxidative stress, and aldehydes that may be 
present in commonly used products.  The results demonstrated that relatively small 
unsaturated aldehydes (6-8 carbons) showed a dramatic decrease in the CYP2A6 activity 
when catalyzing the coumarin 7-hydroxylation reaction. This inhibition could translate to 
a net antioxidant effect, by preventing the formation of reactive oxygen species (ROS), 
particularly in the presence of 2A6-activated nitrosamines, which can be carcinogenic.  It 
was also shown that Cassia and cinnamaldehyde had an inductive effect on Phase II 
enzymes in human hepatoma cells, such as heme oxygenase 1 (HO1) and epoxide 
hydrolase (EPHX), thus exerting a net anti-oxidant effect on the cells as a whole. 
 
REGULATION OF CYTOCHROME P450 2A6 AND 
PHASE II ENZYMES BY UNSATURATED  
ALDEHYDES. 
 
 
 
by 
 
 
Todd Steven Mack 
 
 
 
 
 
 
A Thesis Submitted to 
The Facilty of The Graduate School at 
The University of North Carolina at Greensboro 
in Partial Fulfillment 
of the Requirements for the Degree 
Master of Science 
 
 
 
Greensboro 
2009 
 
 
 
 
 
 
      Approved by 
 
 
      ________________________________ 
      Committee Chair 
ii 
To my Mother and Father, 
Without your encouragement this would not have been possible, 
and to Maria, 
Thank you for you love and support. 
iii 
APPROVAL PAGE 
This thesis has been approved by the following committee of the Faculty of The 
Graduate School at The University of North Carolina at Greensboro.  
 
 
  Committee Chair__________________________________ 
      Committee Members___________________________________ 
      ___________________________________ 
 
 
 
 
 
 
 
 
______________________________ 
Date of Acceptance by Committee 
 
 
 
_______________________________ 
Date of Final Oral Examination 
 
iv 
ACKNOWLEDGEMENTS 
 
 I would first like to thank Dr. Greg Raner for is guidance and financial support 
through my graduate work at UNCG. I would also like to acknowledge Dr. Nadja Cech 
for her assistance through my graduate work. Finally, I would like to thank Dr. Bruce 
Banks for his guidance through my graduate work. 
v 
TABLE OF CONTENTS 
 
Page 
 
LIST OF TABLES .……………………………………………………………………...vii 
 
LIST OF FIGURES …………………………………………………………………….viii 
 
CHAPTER 
 
I. INTRODUCTION ………………..………………………………………1 
 
I. A. Phase I Enzyme- Cytochrome P450….................….…….……….2 
I. B. Cytochrome P450 2A6…………… ………….……….....………...4 
 I. B. i. CYP2A6-Active Site…………………...……..……………5 
I. B. ii.  CYP2A6-Role in Nicotine Metabolism……...…………...6 
I. B. iii. Smoking and CYP2A6 Role on Cancer Risk  ...................7 
I. C. 2A6 Potential Inhibitors…… ………………………………......8 
I. D. Phase II Enzymes- Anti-Oxidant Response…………....………….9 
I. E. Balance of Phase I and Phase II Enzymes…………...….………….13 
II.  MATERIALS AND METHODS ………………………………….......14 
 
II. A. CYP 2A6 Inhibition Screening Method..…………………….....14 
II. A. i. HPLC Analysis………………..…………....………........15 
II. A. ii. K I Determination …………………………………….....15 
II. B. HepG2- Cell Culturing..…………………………………………...17 
II. C. HepG2- Phase II Enzyme Induction. ………………………….....18 
II. D. Total RNA Isolation and Purification.………………………….21 
II. E. RT-PCR of Purified RNA Samples …………………………….23 
II. F. Gel Agarose.………..………….………………….……………….24 
 
III.  RESULTS AND DISCUSSION………………………………………...26 
 
III. A. Inhibition of CYP2A6 by various………………………………...26 
III. A. i. Essential Oils Inhibition Analysis …………………..…28 
III. A. ii. Individual Aldehyde Effects on CYP2A6….………….30 
  III. B. Inductions of Phase II Drug Metabolizing  
 Enzymes by Essential Oils and Aldehydes…………..…………45 
   III. B. i. RT-PCR Internal Controls:   
     β-actin and GAPDH…………………….....…………46 
III. B. ii. RT-PCR Analysis of EPHX1………...............………...47 
III. B. iii. RT-PCR Analysis of HNMT …………....….………...47 
vi 
III. B. iv. RT-PCR Analysis of HAT1……………...……….…...48 
III. B. v. RT-PCR Analysis of Heme Oxygenase-1 ……………..49 
IV.  CONCLUSIONS………………………………………………………54 
 
REFERENCES ………………………………………………………………………..56 
vii 
LIST OF TABLES 
 
 
               Page 
 
 II. 1: List of primer sequences, product size and annealing  
 temperature used to show Phase II enzymes induction.……….………………..24 
 
III. 1: Values of Vmax and Vmax app. from the Michaelis-Menton Plots 
  for each aldehyde….………………………………………...…………………..45 
  
III. 2: Calculated values for KI, KM, KM app for each Unsaturated Aldehyde as listed…..45 
 
 
viii 
LIST OF FIGURES 
 
 
           Page 
 
  I. 1: Coumarin 7-hydroxylation is catalyzed by CYP2A6………………………….....4 
 
  I. 2: Structure of CYP2A6 with coumarin bound to the active site  
          showing Phe 107 π stacking interactions, and Asn 297  
          H-bonding to the oxygen on the substrate (10)……………………………………..6 
 
  I. 3: Metabolism Pathway of Nicotine into Cotinine..………………………...…………7 
 
  I. 4: General overview of the mechanism in which the electrophile                  
         (oxidant) initiates the Nrf2 system…………...………………..………………….11 
 
 II.1:  Experimental setup for dose dependent studies probing  
for the induction of Phase II enzymes in HepG2 cells…………………………..20 
 
 II.2:  Experimental setup for time dependent studies probing  
for the induction of Phase II enzymes in HepG2 cells…………………………..21   
 
III. 1: 7-Hydroxycoumarin standard HPLC chromatogram  
 containing 7-hydroxycoumarin..…………………. ………………….……….27 
 
III. 2: A sample of a HPLC chromatogram obtained with the  
  7-hydroxylation assay……………………………………….……...………......28 
 
III. 3: Plot of percent activity of CYP2A6 using human liver microsomes ………......30 
 
III. 4: Screening of Aromatic Aldehydes, benzaldehyde and cinnamaldehyde ………...32 
 
III. 5: Plot of area vs. coumarin concentration in the presence (red) and absence (green)  
of trans-cinnamaldehyde (0.0605 mM).……………………...……………....34 
 
III. 6: A reaction probing for the activity of CYP2A6 used a broad range of  
inhibitors (saturated aldehydes and carboxylic acid)..………………………….36 
 
III. 7: A reaction probing for the activity of CYP2A6 used a broad range of  
  inhibitors (unsaturated aldehydes)………….. …..…………………………...37 
ix 
 
III. 8: Plot of area vs. coumarin concentration in the presence (red) and absence  
(green) of crotonaldehyde (0.557 mM)...………………...………………….…...40 
 
III. 9: Plot of area vs. coumarin concentration in the presence (red) and absence  
 (green) of trans-2-pentenal (0.464 mM).……………………………………….41 
 
III. 10: Plot of area vs. coumarin concentration in the presence (red) and  
     absence (green) of trans-2-hexenal (0.133 mM)…….…………...…………..42 
 
III. 11: Plot of area vs. coumarin concentration in the presence (red) and  
     absence (green) of trans-2-octenal (0.0754 mM ).......………………………..43 
 
III. 12: Plot of area vs. coumarin concentration in the presence (red) and  
     absence (green) of trans-2-nonenal (0.125 mM)…….....……...…...………..44 
 
III. 13: Gel electrophoresis of the β-actin gene showed a constant band  
     for all of the samples………..…………………………………...……..…...49 
 
III. 14: Gel Electrophoresis of the induction of the HO-1 gene in HepG2 cells,  
in the presence of increasing concentrations of cassia essential oil  
from 0.01 µg/mLto 0.10 µg/mL, with a five hour incubation at 37oC…...….52 
 
III. 15: Gel Electrophoresis of the induction of the HO-1 gene in HepG2 cells,  
in the presence of 0.02 µg/mL cassia oil for 0, 1, 6, and 24 hours  
of incubation at 37oC....………………………………………………….…..52 
 
III. 16: Gel Electrophoresis of the induction of the HO-1 gene in HepG2 cells,  
in the presence of increasing concentrations of cinnamaldehyde  
from 0.01 µg/mLto 0.10 µg/mL, with a five hour incubation at 37oC ..…….53 
 
III. 17: Gel Electrophoresis of the induction of the HO-1 gene in HepG2 cells,  
in the presence of 0.02 µg/mL cinnamaldehyde for 0, 1, 6, and 24 hours  
of incubation at 37oC.……...………………………………………………..53 
 
 
 
1 
CHAPTER I 
INTRODUCTION 
 Cellular oxidative metabolism, including drug and xenobiotic biotransformations, 
may form reactive electrophiles that can covalently modify DNA, proteins and lipids. 
These modified electrophilic biomolecules are thought to cause progression of may 
diseases (2).  The ultimate goal is to gain a better understanding of the rela ionship that 
between Reactive Oxygen Species (ROS) and the body’s defense system against foreign 
chemicals, namely Phase I and Phase II drug metabolism.  Controlling ROS levels is a 
key to preventing and/or controlling the progression of many life threatening diseases.  
The metabolic pathways that remove foreign chemicals (xenobiotics), along with aerobic 
metabolism itself, can generate ROS or other oxidized chemicals that can cause cellular 
damage. These xenobiotics and ROS are eliminated from the body by a multi-step 
pathway involving drug metabolism enzymes. Drug metabolism enzymes are classified 
as either Phase I, II, or III.  Phase I enzymes are involved in the oxidation of xe obiotics, 
such as Cytochrome P450s.  Phase II enzymes deal with the activated compounds that 
Phase I enzymes created by converting them into hydrophilic conjugates facilitating their 
removal (detoxification). Phase III enzymes are involved in eliminating the Phase II 
metabolites from the cells. (3)   
The goal of this work was to gain a better understanding of the involvement of 
drug metabolizing enzymes, Phase I and Phase II enzymes, and the effects that es ential 
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oils, and aldehydes have on the activity of these enzymes. The initial focus was on 
essential oils and various aldehydes that may possess antioxidant properties, by 
preventing the formation of reactive oxygen species (ROS). These oils/aldehydes were 
used to probe the inhibition of human Cytochrome P4502A6 in human liver microsomes 
by utilization of the unique ability of 2A6 to catalyze the conversion of coumarin to 7-
hydroxycoumarin.  Next, induction of Phase II anti-oxidant genes in cultured human 
hepatoma (HepG2) cells by oils and purified aldehydes was monitored using RT-PC  in 
order to assess the potential of these natural products to induce the expression of 
antioxidant enzymes. 
I. A. Phase I Enzyme- Cytochrome P450 
 Cytochrome P450 (CYP) is the most common Phase I enzyme responsible for the 
oxidative metabolism of xenobiotics found in foods, beverages, tobacco products, 
cosmetics, natural products and the majority of drugs on the market today (4). This is a 
very diverse superfamily of hemoproteins found in many different species ranging from 
mammals to archaea (4). These proteins are located all over the body but the majority of 
them are located within the liver.  The most common reaction that cytochrome P450s 
catalyze is a monooxygenase reaction in which a substrate gets one oxygen from 
molecular oxygen incorporated into it and the other oxygen forms water as shown below 
in Equation I. 1 (4). 
  RH + O2 + 2H
+ +2e-  ROH + H2O  Equation I. 1 
Cytochrome P450 are typically abrieviated CYP. The many different subfamilies 
have specific nomenclature that go along with it as well, such as CYP2A6.  The 
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nomenclature is based on gene family, which is indicated by a Arabic numeral following 
the CYP abbreviation, a capital letter follows, indicating the subfamily, followed by 
another number for the which particular gene it is. The active site of the enzyme contains 
a heme iron center that takes part in catalysis (4). 
 Cytochrome P450s in humans are of great interest because of their ability to 
metabolize a broad range of endogenous and exogenous compounds. In the liver, the 
types of the compounds that are metabolized include drugs and a variety of other 
environmental chemicals. In the other areas of the body where cytochrome P450s reside, 
they are involved in a great variety of functions. They are used for hormone synthesis and 
breakdown, cholesterol synthesis, and vitamin D metabolism (2).  
CYPs within the liver account for about 75% of drug metabolism and bio-
activation. Some drugs may act to inhibit or increase specific CYP activity, hereby 
increasing the potential to interact with other drugs. These interactions can have 
significant consequences for patients when taking certain drugs together (4). There are 
many compounds, other than drugs, that can induce or inhibit CYP activity. Natural 
products found in grapefruit juice for example, are well known inhibitors of CYP3A4 and 
it is therefore usually advised that patients avoid drinking grapefruit juice all together 
when taking any medication. Other products that have been shown to interact with major 
CYPs are Saint John’s Wort, which induces CYP3A4, tobacco smoking which induces 
CYP1A2, and starfruit juice which inhibits CYP2A6 (4). 
 The induction of Phase I enzymes has been shown to be mediated via a diverse set 
of nuclear receptors that activate the transcription of these enzymes. These receptors  
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include aryl hydrocarbon receptor (AhR), halogenated aromatic hydrocarbon receptor, 
and also receptors for many steroid-like compounds (6). The AhRs are primarily 
receptors that respond to xenobiotics that enter the body, and their response elements are 
the xenobiotic response elements (XRE), which are recognition motifs for xenobiotic 
compounds (7). Researchers have shown that AhR affects the Nrf2 pathway (a nuclear 
receptor that responds to electrophilic species) which will be discussed further later.    
I. B. Cytochrome P450 2A6 
Cytochrome P450 2A6 (CYP2A6) is one of three members of the CYP2A gene 
subfamily and is the most characterized of the three. CYP2A6 makes up only about 4% 
total hepatic CYP content, but is responsible for the metabolism of specific compounds 
such as nicotine, nitrosamines and aflatoxin B1, as well as several pharmaceuticals (5).  
CYP2A6 is the only cytochrome P450 that is known to catalyze the coumarin 7-
hydroxylation reaction at µM concentrations of substrate, making this compound an ideal 
probe substrate for this enzyme (5). Figure I. 1 shows the reaction catalyzed by 
CYP2A6, which represents the conversion of coumarin into 7-hydroxycoumarin (11). 
 
          
O O OH O O
Coumarin 7-hydroxylation
Coumarin 7-Hydroxycoumarin
 
Figure I. 1: Coumarin 7-hydroxylation is catalyzed by CYP2A6.
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I. B. i. CYP2A6-Active Site 
 The size of the active site of CYP2A6 is 25% of the other drug metabolizing 
CYPs, 2C8, 2C9, and 3A4. Due to tighter packing interactions, the active site is smaller, 
and more compact. Its’ closed active site cavity is complementary to the size, shape and 
hydrophobicity of coumarin, and therefore favors substrates with more planar 
conformations (9). The carbonyl oxygen of coumarin is oriented to accept a hydrogen 
bond from Asn297. The Asn297 is the only polar residue that is accessible to the 
substrate indicating that a mostly hydrophobic substrate is preferred. Another interaction 
between the substrate and the binding pocket arises from the presence of Phe107, giving 
π stacking interactions. Figure I. 2 shows these interactions providing for the proper 
orientation of the substrate, coumarin, so that the 7’ carbon can be oxidized (10). 
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Figure I. 2: Structure of CYP2A6 with coumarin bound to the active site showing Phe 
107 π stacking interactions, and Asn 297 H-bonding to the oxygen on the substrate (10). 
 
 
I. B. ii.  CYP2A6-Role in Nicotine Metabolism 
According to several studies, CYP2A6 is the major P450 associated with nicotine 
metabolism. When nicotine enters the body, CYP2A6 oxidizes about 70% - 80% of the 
nicotine inhaled, by C-oxidation into cotinine (12).  Cotinine is then further hydroxylated 
by CYP2A6, or is excreted from the body.  Nicotine metabolism is very complex; it is not 
only oxidized into cotinine, but forms many other different products that have to go 
through further changes before excreted from the body. Figure I. 3 depicts the 
mechanism by which nicotine gets oxidized by CYP2A6 into cotinine. 
Asn 297 
Phe 107 
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Figure I. 3: Metabolism Pathway of Nicotine into Cotinine. CYP2A6 catalyzes the 
convertion of nicotine into the imminium ion and also the hydroxylation of cotinine into  
3’hydroxy-cotinine. Aldehyde Oxidase converts the imminium ion into Cotinine. 
 
I. B. iii. Smoking and CYP2A6 Role on Cancer Risk   
It has been shown that inactivation of the CYP2A6 enzyme can alter nicotine 
inactivation rates and has the potential to alter smoking patterns (12). CYP2A6 in not 
generally associated with any adverse affects of drug metabolism. This suggests that 
inhibition of CYP2A6 would not alter drug metabolism. Researchers have found that a 
common inhibitor of CYP2A6, methoxsalen, decreases nicotine metabolism and 
smoking, suggesting that an inhibitor may be useful for smoking cessation (10). These 
studies underscore the need for further research on the CYP2A6, and in particular, 
identification of inhibitors of the enzyme.  
 Kamataki et. al. (25) have shown that CYP2A6 is responsible for all of the 
mutagenic activation of the tobacco related N-nitrosamines. They found a CYP2A6 
polymorphism in Japanese that contained a deletion CYP 2A6*4C. They found that 
people that contained this deletion were unable to activate these tobacco related N-
nitrosamines, thus showing a lower susceptibility to lung cancer that was induced by 
tobacco smoke. The researchers found that the frequency of the CYP2A6 deletions were 
lower in lung cancer patients when compared with healthy individuals. This suggested 
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that these healthy individuals had a resistance to carcinogenesis from N-nitrosamines 
because of the poor metabolism of them. They deduced from these findings that CYP2A6 
is responsible for enhancing the risk for lung cancer. (25)  
I. C. 2A6 Potential Inhibitors 
 The current study will focus on specific essential oils and aldehydes that have the 
ability to inhibit CYP2A6.  Essential oils are the volatile lipid (oil) soluble part of 
different plants (4). These oils can be taken out of the plant matter by steam distillation. 
A variety of different aldehydes are present in each of the different oils that have been 
selected for this study. Cassia and cinnamon bark oil contain the aldehyde 
cinnamaldehyde, in fact based on GC/MS analysis of our Cassia oil, it was found that 
80% of the total ion composition was cinnamaldehyde, which has the highest content of 
the essential oils looked at. Essential oil of Lemongrass on the other hand contains nearly 
55% citral (4). The ability of these oils and there constituents to inhibit P450 2A6 may be 
of significance with regard to the role of 2A6 in nicotine or nitrosamine metabolism as 
noted previously. 
 The interest in aldehydes as inhibitors of P450 2A6 stems from prior studies by 
Raner et. al. indicating that aldehydes represent a general class of cytochrome P450 
inhibitors (13). In particular, unsaturated aldehydes showed the greatest potency in the 
inactivation of several mammalian cytochrome P450s. The use of a series of related 
unbranched saturated and unsaturated aldehydes in the current study provides a means of
probing structure/function relationships regarding inhibition of the smaller binding 
pocket of CYP 2A6 (10). CYP 2A6 has a few key amino acid residues that have been 
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shown above to play an important role in the binding specificity of inhibitors. These key 
amino acids are Phe 107 which provides for the π stacking interactions that would 
account for the preference of the unsaturated aldehydes or trans-cinnamaldehyde over 
saturated aldehydes (Figure I. 2). Also, Ans 297 has a H-bond to donate to a substrate 
and gives a higher preference for an inhibitor with a H-bond acceptor. 
I. D. Phase II Enzymes- Anti-Oxidant Response 
Vertebrates have developed a response network to cellular stresses that control 
reactive electrophiles by stabilization and activation of Nrf2, a transcriptional activator 
for a wide variety of antioxidant genes. Free radicals can be generated from exogenous 
and endogenous sources. Exogenous radicals occur from environmental oxidants such as 
O3 and NO2, ionizing radiation and bioactivated xenobiotics and drugs (18). Endogenous 
radicals can be generated within the cell from a one-electron transfer, to oxygen via 
monooxygenase enzymes such as cytochrome P450s. They can also be generated in the 
mitochondria via the production of ATP.  Oxidative phagocytosis also result in free 
radicals generated in the lysosomes, and in the cell membrane free radicals result from 
the synthesis of inflammatory mediators (15).  
  The Phase II enzymes can be induced by a multitude of chemical species, 
including many of those found in the foods that we eat (16). Past research has shown that 
green tea polyphenolic compounds are good inducers of several Phase II enzymes i the 
body (20). There are two different types of inducers of Phase II enzymes, bifunctional 
and monofunctional. Bifunctional inducers act to induce Phase I and Phase II enzymes. 
Consequently, a bifunctional inducer results in an upregulation of Phase I enzymes 
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increasing the production of strong electrophiles, thereby promoting carcinogenesis, but 
also contributing to the production of Phase II enzymes. Monofunctional inducers only 
induce Phase II enzymes and consist of Michael addition acceptors, quinones and  
isothiocyanates. (18) The biochemical mechanism by which Phase II genes ar  induced is 
becoming clear.  Under basal conditions, Nrf2 acts by complexing with Keap1 in the 
cytosol, and this complex is regulated via ubiquitination by CUL3 (18). Electrophiles 
modify the Keap1 and Nrf2 which allows Nrf2 to enter the nucleus and bind to promoter 
regions of target genes that contain antioxidant response elements and electrophilic 
response elements (ARE/EpRE), resulting in the induction (Figure I. 4) of over two 
hundred target genes (17).  
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Oxidant
Cul3
Keap1
Nrf2
Antioxidant proteins
Keap1
Cul3
Nrf2
  
Figure I. 4: General overview of the mechanism in which the electrophile (oxidant) 
initiates the Nrf2 system. Once Nrf2 is activated and released from Keap1 it can move 
freely into the nucleus and turn on the ARE (18). 
 
AREs act to regulate a multitude of antioxidant genes which respond to oxidative 
stressors such as reactive oxygen species. EpREs defend against electrophilic toxicity by 
controlling production of Phase II enzymes that detoxify electrophilic reactiv   
metabolites (19). ARE/EpRE regulate the genes that code for antioxidant proteins, such 
as glutathione-S-transferase (GST), NAD(P)H: quinone oxidoreductase (NQO), and 
epoxide hydrolases (EPHX) (20). EPHX is responsible for metabolism of reactive 
epoxides, such as those found in cigarette smoke. 
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Genes that are responsive to this regulatory pathway include those involved in 
Phase II xenobiotic detoxification, antioxidant response, apoptosis, cell growth, and 
proteasomal activity (18). Common inducers of the system are H2O2, superoxide, 
hydroxyl radicals, quinones, and other electrophiles generated via lipid peroxidation (19). 
These electrophiles trigger a response by the Nrf2 system in which antioxidant response 
elements are turned on.  The aldehyde groups present in the selected oils are of great 
interest due to their similarities to known electrophile inducers that are responsible for the 
induction of these Phase II enzymes. Recent studies have shown that electrophili groups, 
such as aldehydes, may play a role in Nrf2-dependent induction of antioxidant genes in 
rats (11). For example, N-iodoacetyl-N-biotinylhexylenediamine (IAB) and polyphenols 
have been shown to be activators of the Nrf2 pathway (18). The hypothesis on which the 
current study is based is that the aldehyde constituents of the essential oils wil play a role 
in the induction of antioxidant genes in HepG2 cells, causing a net antioxidant effect in 
vivo.  
Prior studies aimed at understanding the Nrf2 pathway have focused on one of 
several different genes that are known to respond to oxidative stress. For example, He e 
Oxygenase is a well known Phase II antioxidant protein that has two subtypes (22). Heme 
Oxygenase-1 (HO-1) catalyzes the breakdown of heme into two products, biliverdin and 
CO. Biliverdin reductase then converts biliverdin to bilirubin, which is a known protein 
antioxidant. (22) HO-1 is the rate limiting factor within the heme degredation. HO-1 is an 
inducible enzyme whereas HO-2 is a constitutive enzyme, not responding to oxidative 
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stressors. An increase in HO-1 mRNA levels is a response from oxidative stress caused 
by the depletion of reduced glutathione levels in the cell.  
HO1 is also being used in the current study because of its known induction via a 
Nrf2-dependent pathway. Prior studies using green tea extracts have also pointed toward 
other potential antioxidant enzymes of interest which include histone-acetyl-transferase-1 
(HAT1), Epoxide hydrolases (EPHX), and histamine N-methyl transferases (HNMT) 
(23). In the prior micro array experiments, all of these genes were induced in response to 
the presence of green tea extract, a suspected Nrf2 activator (20).  
I. E. Balance of Phase I and Phase II Enzymes 
The complex interplay between Phase I and Phase II enzymes can have a 
significant impact on the oxidative state of the cell, and can significantly impact the risk 
for developing diseases such as cancer (24).  Phase I enzymes are involved in the 
oxidation of xenobiotics, and cytochrome P450s are the dominant enzymes in this class. 
In most cases, these xenobiotics are activated to form more hydrophilic species that can 
be removed more easily. Often, xenobiotics are activated to form electrophilic or free 
radical metabolites that can result in DNA adduct formation and oxidative stress.  Phase 
II enzymes are required to relieve or prevent this oxidative stress, converting the 
activated metabolites to unreactive water soluble products to be excreted from the cell by 
Phase III enzymes (3).   
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CHAPTER II 
MATERIALS AND METHODS 
 
II. A. CYP 2A6 Inhibition Screening Method 
The Michaelis-Menton model for enzyme inhibition has been used to look at the 
effects of the various essential oils on CYP2A6. The oils used included Cinnamon leaf, 
Lemon Grass, Coriander, and Cassia. In addition, a series of aldehydes were studied 
including α,β unsaturated aldehydes and saturated aldehydes ranging from four to twelve 
carbons. [E] Oct-2-enoic acid and Octenoic acid were also screened for inhibitory activity 
against CYP2A6.  The assay that was used to measure inhibition of CYP2A6 was one 
that utilizes the conversion of coumarin into 7-hydroxycoumarin. The procedure was 
modified from that of Waxman and Chang, in which fluorometric analysis of the 
hydroxycoumarin was used [24]. Each inhibitor was initially diluted from 5 µL into 100 
mL of water to make a stock solution.  Conditions used for the screening experiment in 
the current study were as follows: Liver microsomes (1mg) were incubated in a reaction 
mixture containing 30 µM coumarin, potassium phosphate buffer containing 3.3mM 
MgCl2, (pH 7.4, 100 mM), serial dilutions of inhibitor (ranging from 5 µM to 600 µM for 
the purified aldehydes and 0.5 µg/mL to 37.5 µg/ mL for the crude oils), and DI H20, 
added to give a volume of 450 µL. The reaction was initiated using 50 µL of a NADPH-
regenerating system containing NADP+ (1mM), glucose-6-phosphate (3.3 mM), and 
glucose-6-phosphate dehydrogenase (1 unit/mL), that was incubated for 7 minutes at 
15 
37oC prior to its’ addition. Following a 30 minute incubation at 37 oC the protein was 
precipitated with 0.25 mL of 6% perchloric acid and placed on ice for 10 minutes. 
Samples were centrifuged at 3500 rpm for 10 minutes, and 500 µL of the cleared solution 
and a 7-hydroxycoumarin standard were placed in HPLC vials to be analyzed via HPLC. 
II. A. i. HPLC Analysis 
HPLC anayslis was performed using Shimadzu’s LC-20AT/ Prominence Liquid 
Chromatography system and the samples were detected by the SPC-20A/ Prominence 
UV/Vis Detector at 320 nm. Up to 100 HPLC vials were loaded into the Autosampler and 
40 µL of each sample were injected onto a RP-C18 HPLC column with a mobile phase 
consisting of 45% solution A (94% DI water, 5% methanol, and 1% acetic acid) and 55% 
methanol, at a flow rate of 1mL/min. Standards were used to differentiate the peaks of 
coumarin, and 7-hydroxycoumarin. The coumarin retention time of 6 minutes was 
determined by loading a coumarin standard. The retention time for the product, 7-
hydroxycoumarin was determined using an authentic standard compound injected under 
the same conditions. This standard gave a retention time of 4.5 minutes. The 7-
hydroxycoumarin peaks from each of the reaction samples were integrated to give the 
relative activities of the 2A6 in human liver samples. 
II. A. ii. KI Determination 
Conditions used for determining the KI in the current study were as follows: Liver 
microsomes (1mg) were incubated in a reaction mixture containing a range from 1 µM to 
20 µM coumarin, potassium phosphate buffer containing 3.3mM MgCl2, (pH 7.4, 100 
mM), volume of inhibitor where in the screening conditions ~50% inhibition of 2A6, and 
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DI H20, added to give a volume of 450 µL. The reaction was initiated using 50 µL of a 
NADPH-regenerating system containing NADP+ (1mM), glucose-6-phosphate (3.3 mM), 
and glucose-6-phosphate dehydrogenase (1 unit/mL), that was incubated for 7 minutes at 
37oC prior to its’ addition.  Following a 30 minute incubation at 37 oC the protein was 
precipitated with 0.25 mL of 6% perchloric acid and placed on ice for 10 minutes. 
Samples were centrifuged at 3500 rpm for 10 minutes, and 500 µL of the cleared solution 
and a 7-hydroxycoumarin standard were placed in HPLC vials to be analyzed via HPLC. 
 Michealis Menton plots were used in order to determine the KI for each aldehyde 
of interest. Each KI was found by plotting V vs. [S] at a range of increasing concentration 
of coumarin in the presence and absence of an inhibitor. The inhibitor concentration was 
chosen based on screening experiments carried out to test the relative potency of each.  
Concentration of inhibitor, [I],  was chosen where in the screening conditions ~50% 
inhibition of 2A6 was observed. The relative activity was plotted vs. concentration of 
coumarin using Slide Write Plus (by Advanced Graphics Software, Inc.). The Michealis 
Menton equation (Equation II.1) was used to determine the maximum velocity without 
inhibitor present (Vmax), and with inhibitor present (Vmax app), the substrate concentration 
at which in the enzyme is ½ the Vmax (Km), and the substrate concentration in the 
presence of inhibitor when the enzymes is at ½ the Vmax app (Km app). 
    Vo= Vmax * [S]    Equation. II.1. 
              Km + [S] 
Using Equation II.2, the KI was calculated using the inhibitor concentration.   
          Km app = Km (1+ [I]/K I)   Equation II.2. 
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The data supports the assumption that the inhibitors show the competitive model of 
inhibition, and Vmax was relatively unchanged by the presence of the inhibitor, for most 
of the compounds, indicating a competitive mode of inhibition. 
II. B. HepG2- Cell Culturing 
 All procedures were carried out in a class II Laminar flow hood in a clean room.  
Human hepatoma cells (HepG2) were obtained from ATCC Laboratories cryopreserved 
in liquid nitrogen. The cells were rapidly thawed immediately before use. The cells were 
seeded onto an adherent T75 flask with Dulbecco’s Modified Essential Medium with 
4500 mg glucose/L to which 10% Fetal Bovine Serum was added. The cells were grown 
at 37oC until they reached 80% confluence (about 4 days). To split the cells the media 
was removed by aspiration and the cells were immediately washed with 3 mL of 
phosphate buffered saline (PBS) without Ca2+/Mg2+. This was to remove any residual 
trypsin inhibitor that may have been present. The PBS was then removed by aspiration 
and 3 mL Trypsin/EDTA (0.05% Trypsin) was added to each flask and the cells were 
bathed in this solution for 5 minutes. Cells were then loosened from the flask by tapping 
with the heel of the hand. For every 1 mL of Trypsin/EDTA added, at least 1 mL of 
media was needed to stop the trypsin reaction (3 mL media for a T75, 1 mL media for a 
T25). The cell suspension was then drawn into a glass pipette several times to mix 
thoroughly and 1 mL aliquots of the suspension were taken out and placed in T25’s along 
with 4 mL of media to bring up to a final volume of 5 mL. The T25 flasks were grown 
out and further split into new cultures such that there were sets of four T25 flasks for use
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in the induction of the phase II enzymes which will be discussed further in the next 
section. 
 For every passage of the cells, a single T75 flask was used to generate a stock
culture for cryopreservation. This was done by taking either a T75 culture flask or 
seeding a new T75 flask from a T25 and aspirating the culture media once the cells 
reached 80% confluence.  The cells were then washed with 3 mL of PBS.  The cells were 
then trysinized for 5 minutes and neutralized by adding an equal volume of DMEM. The 
flasks were tapped to remove cells from the surface, at which point they became 
suspended in the media. The cell suspension was drawn into a glass pipette and transfered 
to a 50 mL Falcon tube. The cells were spun down at 1000 rpm for 5 minutes into a pellet 
at room temperature and the supernatant was aspirated off. The cells were resusp nded in 
5 mL DMEM containing 10% DMSO and the cells were split into 1 mL aliquots and 
were transferred to cryovials, rapidly transferred to a freezer container and placed at -
70oC for 4-5 hrs. The cells were then placed into the liquid nitrogen dewar for long term 
storage. 
II. C. HepG2- Phase II Enzyme Induction 
In order to show the induction of antioxidant genes by essential oil, four samples 
of HepG2 cells were grown in 5 mL of DMEM in T25 flasks until the cells reached 80% 
confluence. Figure II. 1 shows the experimental setup of the incubations that were 
performed for the dose dependent experiments with cassia and trans-cinnamaldehyde. 
Cells were treated with various amounts of cassia oil and cinnamaldehyde and control 
cells were treated with equal quantities of sterile water. For the control, 4 mL of DMEM 
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and 1 mL of sterile water was added. Dose 1 through 3 contained 4 mL of DMEM and 1 
mL of an oil/aldehyde mixture: 10 µg/mL, 20 µg/mL, and 100 µg/mL, respectively. 
Following treatment with inducer, cells were grown for an additional 5 hours at 37oC. For 
the time dependent study the control cells were immediately harvested without any 
further incubations at 0 minutes. For the others, they contained 1 mL of 20 µg/mL
inducers (cassia and cinnamaldehyde) and 4 mL of DMEM and were incubated at 37oC
time intervals of 1, 6, and 24 hours. 
Figure II. 2 shows the experimental setup of the incubations that were performed 
for the time dependent experiments with cassia and trans-cinnamaldehyde. Te cells were 
treated with 1 mL of 20 µg/mL cassia and cinnamaldehyde and 4 mL of DMEM.  The 
control cells were immediately harvested and the RNA was isolated. Time 1 through 3 
were incubated at 37oC for 1 hour, 5 hours, and 24 hours, respectively.  
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Figure II.1:  Experimental setup for dose dependent studies probing for the induction of 
Phase II enzymes in HepG2 cells.  T75 culture flask were split at 80% confluence into 
four experimental T25 culture flasks.  Concentrations of 10 µg/mL, 20 µg/mL and 100 
µg/mL of cassia oil and trans-cinnamaldehyde administered to the T25 as mentioned 
above.  After a 5hr incubation the cells were harvested for RNA isolation. 
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Figure II.2:  Experimental setup for time dependent studies probing for the induction of 
Phase II enzymes in HepG2 cells.  T75 culture flask were split at 80% confluence into 
four experimental T25 culture flasks.  A concentration of 20 µg/mL of cassia oil and 
trans-cinnamaldehyde was administered to the T25 as mentioned above.  After a 0, 1, 5, 
and 24 hour incubation the cells were harvested for RNA isolation. 
 
 
II. D. Total RNA Isolation and Purification 
Prior to RNA isolation, the solutions were prepared by adding 200 µL Beta-
mercaptoethanol to 10 mL of the SV RNA Lysis Buffer, 275 µL of nuclease free water to 
the DNase I, 100 mL of 95% ethanol to the SV RNA Wash Solution and 8 mL 95% 
ethanol to the SV DNase stop solution. The cells were harvested and the total RNA was 
isolated using the SV total RNA isolation system by Promega. Cultured Cells were 
harvested by first aspirating off the DMEM and washing with 1 mL PBS. The 1mL of 
RNA lysis buffer was added to each flask to which the cells were adhered.  After bathing 
the cells for 1 minute in the buffer, a cell scrapper was used to physically remove the 
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cells from the flask, where they became suspended in the lysis buffer.  Following lysis, 
175uL of the lysed sample was mixed with 350 µL of the RNA dilution buffer in a 1.5 
mL eppindorf tube and were inverted several times to fully dilute the RNA. Samples 
were then incubated at 70oC for three minutes (longer than three minute incubation may 
compromise the RNA). Samples were centrifuged for 10 minutes at 14,000 x g at room 
temperature to pellet the remainder of the unwanted cell debris leaving RNA in the 
Dilution Buffer. 
The total isolated RNA was purified by the centrifugation method as follows: the 
cleared lysate that contained the RNA was transferred to a new tube to be purified.  A 
200 µL volume of 95% ethanol was added and the entire content of the tube was 
transferred to the spin column assembly and then centrifuged for one minute at 14,000 x 
g. After every centrifugation in the purification, the liquid in the collection tube was 
discarded. The RNA was then washed with 600 µL of RNA wash solution. DNase 
incubation mix, containing 40 µL yellow core buffer, 5 µL 0.09M MnCl2 and 5 µL 
DNase1 enzyme was combined and then added to each reaction making sure that the 
entire membrane was covered. The DNase solution was incubated for 15 minutes at room
temperature. To stop the reaction, 200 µL of DNase stop solution was added to the spin 
basket and then centrifuged for one minute at 14,000 x g. Two RNA washes were then 
performed by adding 600 µL and 250 µL of RNA Wash Buffer followed by 
centrifugation for one minute and two minutes, respectively. The spin basket was then 
placed in an elution tube and by adding 100 µL of Nuclease-Free water and centrifuging 
for one additional minute, the RNA was eluted. The purified RNA was then stored at -
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70oC in microfuge tubes.  The RNA was quantified by spectral absorption by adding 0.6 
mL of DI water and 5 µL purified RNA and mix briefly into a cuvette. The absorption 
was read at 260 nm to give a crude amount of the RNA present in each sample. Using 
Beer’s Law A = e*C* l, with an extinction coefficient of 25 µl/µg/cm the concentration 
of the RNA can be calculated.  
II. E. RT-PCR of Purified RNA Samples 
Following the RNA isolation, RT-PCR was performed to show the induction of 
the Phase II enzymes using 1.21 µg/µl of RNA. The genes that were probed include 
epoxide hydrolase (EPHX1), histone acetyltransferase1 (HAT1), histamine N-
methyltransferase (HNMT), and Heme Oxygenase 1 (HO-1). The internal co trols used 
were β-actin and GAPDH. Table II. 1 shows the 5’-3’ sequence of the upstream and 
downstream primers used for the amplification of these enzymes as well as the 
corresponding expected product sizes.  All primers were synthesized and purchased from 
Integrated DNA technologies Inc. (IDT). The 25 µL reaction, consisted of a final 
concentration of 1x AMV/Tfi Reaction Buffer (Promega), 1mM MgSO4, 0.2 mM dNTPs, 
1 µM forward and reverse primers, 1.21 µg template DNA, Tfi DNA polymerase (0.1 
u/µL), AMV Reverse Transcriptase (0.1u/µL) and Nuclease free water to reach the final 
volume. RNA was first converted into cDNA via the reverse transcriptase (RT) reaction, 
which was carried out at 45oC for 45 minutes. Following RT, the PCR reactions were run 
using the Gene Amp PCR System 9600 (Perkin Elmer Cetus), with an initial denaturation 
and deactivation of reverse transcriptase at 95oC for 2 minutes and were followed by PCR 
cycling for 30 cycles. The cycles consisted of a denaturing step at 95oC for 30 seconds, 
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followed by a 60 second annealing temperature that varied with the each different primer 
(shown in figure 1), and then an extension step of 2 minutes at 72oC.  The sample was 
cooled to 4oC until it was removed from the thermal block for analysis.  The samples 
were then either immediately analyzed by agarose gel electrophoresis r stored at -20oC 
for use at a later time. 
 
Table II.1- List of primer sequences, product size and annealing temperature used to 
show Phase II enzymes induction. 
 
II. F. Gel Agarose 
The RT-PCR products were then visualized using gel electrophoresis. A 2% gel 
was made using 0.6 g of GCA Agarose (ISC Bio Express) and 35 mL 1X TRIS-Acetate  
EDTA solution (TAE) containing 40 mM TRIS-Acetate, and 1 mM EDTA. The solution 
was placed in a microwave a heated into totally liquefied and was poured into the gel box 
and was allowed to set for an hour. Then the gel was added to the BioRad Mini-Sub Cell 
Primer Sequence 
Product 
(bp) Annealing temperature 
    
β-actin 
5' AGCGAGCATCCCCCAAAGTT 3'; 
285 56 5' GGGCACGAAGGCTCATCATT 3'  
GAPDH 
5' AGAAGGCTGGGGCTCATTTG 3';  
258 57.5 5' AGGGGCCATCCACAGTCTTC 3'  
 5' CAGTTCTCAGTCCAACAGGAGGAG 3';   
HAT1  5'CGGTCGCAAAGAGCGTAGCTCCA 3' 215 62  
HNMT 
5' GGACAAGAAGCTGCCAGGC 3';  
219 60 5' CTCGAGGTTCGATGTCTTGGC 3'  
EPHX1 
5' GGCTTCTCAGAGGCATCCTCC 3';  
273 59   5' CCACATCCCTCTCAGTGAGGCC 3'  
 5' CAGGCAGAGAATGCTGAGTTC3'    
HO1 5' GCTTCACATAGCGCTGCA 3' 270 55  
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GT box such that the wells were closest to the black terminal and 1 X TAE buffer was 
added up to the fill line. Sample loading buffer (4 µL) was added to each sample and then 
10 µL aliquots of the samples containing the amplified DNA were loaded into each well. 
A 5 µL sample of a 100-1300bp ladder was also analyzed as a standard to show band 
sizes. The gels ran at 110 volts using the BioRad Power Pac 300 for approximately 45 
minutes until the bromophenol blue tracking dye reached approximately ¾ of the way to
the end of the gel. The gel was visualized by staining with 30 µL of 0.625 mg/mL 
ethidium bromide for 30 minutes in 1 X TAE buffer and then destained using DI water 
for 15 minutes. The gel was then visualized under UV light and imaged using a Kodak 
digital imaging system. 
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CHAPTER III 
 
RESULTS AND DISCUSSION 
 
 
III. A. Inhibition of CYP2A6 
 The interaction of CYP2A6 with a diverse set of aldehydes leads to inhibition of 
the enzyme, which has been shown using an enzymatic assay for the 7-hydroxylation of 
coumarin with HPLC detection. This assay was developed in our lab for the purpose of 
high throughput HPLC analysis of P450 2A6 inhibitors. Figure III. 1 shows a HPLC 
chromatogram of a 7-hydroxycoumarin standard. The reaction mix loaded contained all 
of the components in the assay except for coumarin. The peak that was seen at 2.5 was 
identified as NADPH by leaving out NADPH in the following reaction. The peak at 4.5 
minutes was determined to be 7-hydroxycoumain. A peak with a retention time of around 
4.5 minutes was observed in subsequent experiments in which the substrate coumarin 
was incubated with human liver microsomes and NADPH. In control experiments where
NADPH was omitted, this peak was not observed, comfirming its identity in the catalytic 
assays. Prior studies involving P450 2A6 utilized a fluorescent method of detection of the 
7-hydroxycoumarin, however in this lab, fluorescence measurements were inconsistent 
probably due to the non-specific nature of the assay. The HPLC method was therefore 
developed to overcome these difficulties.  
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Figure III. 1: 7-Hydroxycoumarin standard HPLC chromatogram containing 7-
hydroxycoumarin. The other reaction components are described in the experimental 
section, and lacks coumarin. The peak at 4.5 minutes was identified as the 7-
hydroxycoumarin standard. The small peak at 2.3 min. was due to a small amount of 
NADPH.  
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Figure III. 2: A sample of a HPLC chromatogram obtained with the 7-hydroxylation 
assay. The peak with a retention time of 6 minutes was identified as coumarin, at 4.5 
minutes the peak of 7-hydroxycoumarin was seen, and at a retention time of 2.5 min. 
NADPH was seen. These retention times were determined by comparison with standards 
each of the compounds. This sample contained 20 µM coumarin, potassium phosphate 
buffer containing 3.3mM MgCl2, (pH 7.4, 100 mM), 0.0754 mM trans-2-octenal and 
1mM NADPH and was incubated for 7 minutes at 37oC.     
 
III. A. i. Essential Oils Inhibition Analysis 
 Initial screening experiments in this lab indicated that the essential oil of cassia 
significantly inhibited CYP2A6. The essential oils were included in the reaction of 
CYP2A6 with 30 µM coumarin with increasing the concentration of oil from 0.5 µg/mL 
to 37.5 µg/mL.  Figure III. 3 shows the inhibition of P450 2A6 by the essential oils of 
cassia, cinnamon leaf, coriander, and lemongrass. As seen in this figure, of these our 
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oils, only cassia inhibited the activity of 2A6 by >50% at concentrations as low as 12.5 
ug/mL. In fact, lemon grass, which was the next most potent oil showed only 50% 
inhibition where cassia oil inhibited 2A6 activity by 80% at the highest concentration. 
For this reason cassia oil was selected for subsequent studies with regard to its inhibition 
on P450 2A6. Since the main aldehyde in cassia oil is cinnamaldehyde, it is likely that 
this compound is responsible for inhibition. From this it can be estimated that the amount 
of inhibition for cinnamaldehyde should exceed that of the essential oil of cassia, 
assuming cinnamaldehyde is the only inhibitory compound present in the oil. The 
essential oil of lemongrass, which contains 55% citral, showed inhibition around 50% on 
CYP2A6 at the highest concentration. The cinnamon leaf oil showed little to no 
inhibition on CYP2A6. Cinnamon Leaf oil contains 70-90 % eugenol and only 5% 
cinnamaldehyde. Coriander shows roughly 20% inhibition of the activity of CYP2A6 
(contains 20% hydrocarbons and 45-70% d-linalool, and coriandrol). All of these 
observations point to cinnamaldehyde as a relatively potent chemical inhibitor of P450 
2A6. 
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Figure III. 3: Plot of percent activity of CYP2A6 using human liver microsomes in the 
presence of 30 µM coumarin, different essential oils from 0.5 µg/mL to 37.5 µg/mL and 1 
mM NADPH. 
 
 
III. A. ii. Individual Aldehyde Effects on CYP2A6 
 The effects of essential oils as inhibitors of CYP2A6 have been shown most 
effectively with cassia and lemon grass. The effect on CYP2A6 that the cinnamaldehyde 
may posses, based on the results shown for the essential oil of cassia, was further 
examined because of fact that cinnamaldehyde composed of approximately 80% of the 
cassia oils.  Also a variety of saturated and unsaturated aldehydes were used to probe for 
inhibition on CYP2A6 activity in order to better understand the structural features of the
aldehydes that make them inhibitors of this particular cytochrome P450.
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III. A. ii. a. Aromatic Aldehydes as CYP2A6 inhibitors 
 To probe the effect that aromatic aldehydes have on CYP2A6 the compounds 
cinnamaldehyde and benzaldehyde were used. CYP2A6 when in the presence of 
coumarin and increasing concentrations of cinnamaldehyde shows 89.4% inhibition at the 
highest concentration of inhibitor, as shown below in Figure III. 4. Even at 12.5 µg/mL, 
inhibition of 2A6 by cinnamaldehyde was nearly 60%, which is consistent with observed 
inhibition of 2A6 using cassia oil. Benzaldehyde was another aromatic aldehyde of 
interest because of its structural similarities to cinnamaldehyde. When in the presence of 
increasing amounts of benzaldehyde and constant concentrations of coumarin, CYP2A6 
activity drops to 23.1% activity at the highest concentration of inhibitor. The screening 
results for benzaldehyde are shown in F gure III. 4. Concentrations are shown in 
screening data using µg/mL but in Michaelis Menton plots concentrations are converted 
into mM units using the molecular weight of the aldehydes.  Although not as potent as 
cinnamaldehyde in its inhibition of 2A6, benzaldehyde was still a moderately potent 
inhibitor.  
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Figure III. 4:  Screening of Aromatic Aldehydes, benzaldehyde and cinnamaldehyde. 
The reaction probing for the activity of CYP2A6 used a range from 0 µg/mL to 37.5 
µg/mL aldehydes, 30 mM coumarin, human liver microsomes, and NADPH. 
  
To probe further into the effects of the essential oil of cassia, cinnamaldehyde was 
examined using the Michaelis Menten model of enzyme kinetics and inhibition. CYP2A6 
was incubated with cinnamaldehyde and coumarin using different concentrations of 
substrate ranging from 1 µM to 20 µM. The experiment was carried out in the presence 
and absence of cinnamaldehyde (0.0605 mM) and the relative activities were plotted
against the concentration of coumarin as in the Michaelis Menton model. Based on the 
data shown in this plot (Figure III. 5), a Vmax and KM were calculated in the absence an 
presence of cinnamaldehyde. Based on the observation that Vmax was unaffected, the 
competitive model of inhibition was used to calculate a KI of 0.0214 mM for 
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cinnamaldehyde.  Based on the obtained values for KI f the cinnamaldehyde in this 
experiment, and its relative abundance in cassia oil, we can assume that cinnamaldehyde 
is primary inhibitor of CYP2A6 contained in the cassia oil. 
The ability of benzaldehyde and trans-cinnamaldehyde to inhibit the enzyme is 
attributed to the presence of the unsaturated bonds in the compounds. These compounds 
both have a benzyl group within the molecule which mimics part of the substrate, 
coumarin.  Even though coumarin has a bicyclic ring, trans-cinnamaldehyde closely
resembles coumarin’s size and shape, which could possibly result in its’ ability to 
compete in the enzyme’s active site.  
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Figure III. 5: Plot of area vs. coumarin concentration in the presence (red) and absence 
(green) of trans-cinnamaldehyde (0.0605 mM).  Reactions contained inhibitor, human 
liver microsomes, a range of substrate concentrations from 0 µM to 20 µM, and 1 mM 
NADPH.
 
  
III. A. ii. b Structure/Activity Relationship: Saturated vs. Unsaturated Aldehydes
 To analyze the effect of bond saturation on the inhibition of CYP2A6, a series of 
saturated and unsaturated aldehydes were used. First, inhibition screening of a broad 
range of saturated and unsaturated aldehydes were performed using increasing amounts 
of aldehydes in the presence of CYP2A6 and coumarin. Figure III. 6 shows a broad 
range screen of aldehydes containing saturated bonds, as well as a select set of es ential 
oils, and acids. These aldehydes showed a relatively low amount of inhibition on CYP 
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2A6 activity. Undecylic aldehyde was the only saturated aldehyde to show any kind of 
inhibition to a 77% activity of the enzyme at the highest concentration 37.5 µg/mL of 
aldehyde. All of the other compounds have little to no inhibition on CYP 2A6. Figure 
III. 7 shows the percent inhibition of CYP 2A6 with increasing concentrations of 
unsaturated aldehydes. The most notable compounds are trans-2-hexenal, and trans-2-
octenal.  Trans-2-hexenal shows 59% activity of the enzymes at the mid-range 
concentration and at the high end concentration the enzymes is only 27% active. Trans-2-
octenal shows at the highest concentration of aldehyde the activity droped to merely 23%.   
The smallest compounds such as trans-2-pentenal and crotonaldehyde inhibited 2A6 at 
only 82% enzymes activity when in the presence of crotonaldehyde at the highest
concentration, and 60.4% activity of the enzymes with trans-2-pentenal present at th  
highest concentration.  Trans-2-nonenal shows inhibition to about 44% activity of the 
enzyme. 
Based on these studies it appeared that the degree of saturation of the aldehyde 
influenced the potency of inhibition of the enzyme. Based on the active site of CYP 2A6 
it might be predicted that the unsaturated aldehydes would be preferred, which is 
consistent with the screening data from Figure III. 6 and Figure III. 7. 
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Figure III. 6: The reaction probing for the activity of CYP2A6 used a range of inhibitors 
(saturated aldehydes and carboxylic acids) from 0 µg/mL to 37.5 µg/mL, 30 mM 
coumarin, human liver microsomes, and NADPH. 
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Figure III. 7: The reaction probing for the activity of CYP2A6 used a range of inhibitors 
(unsaturated aldehydes) from 0 µg/mL to 37.5 µg/mL, 30 mM coumarin, human liver 
microsomes, and NADPH. 
 
III. A. ii. c. Structure/Activity Relationship: Aldehyde Chain Length 
 Once the effects of saturated and unsaturated aldehydes were differentiat d, and 
that it was determined that unsaturated aldehydes were more inhibitory than saturated 
aldehydes, the focus was turned to the effect of the chain length on CYP2A6. Figure III. 
7 shows the broad range screen of the unsaturated aldehydes with increasing 
concentration. As seen, the activity of CYP2A6 decreases the most around 6-8 carbon 
chain lengths. In order to determine the potency of these compounds, Michaelis-Menton 
plots were generated in the presence and absence of inhibitor and relativeactiviti s of 
2A6 were plotted against the concentration of the substrate coumarin (1 µM to 20 µM). A 
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Michaelis-Menton plot was created for each of the following aldehydes: crotonaldehyde, 
trans-2-pentenal, trans-2-hexenal, trans-2-octenal, trans-2-nonenal, and trans-
cinnamaldehyde. Each individual aldehyde was used at the approximate concentration 
that led to 50% inhibition on CYP2A6 in the screening reactions and was analyzed by 
plotting the integrated product peak area vs. substrate concentration. Figures III. 8 - III. 
12 are Michaelis-Menton plots that show the formation of 7-hydroxycoumarin with and 
without aldehyde with increasing concentrations of coumarin. In some cases the mode of 
inhibition appeared to be competitive based on a constant Vmax with and without inhibitor 
and the others showed a slight difference in the Vmax and a percent error reasonable to 
make the assumption that they are competitive inhibitors, along with an increase in the 
KM with the presence of the inhibitor. The Michaelis-Menton plot using 0.557 mM 
crotonaldehyde is shown in Figure III. 8.  Crotonaldehyde’s calculated value for KI was 
0.205 mM showing a moderate potency compared to the other aldehydes. Figure III. 9 
shows the Michaelis-Menton plot was 0.464 mM trans-2-pentenal. Trans-2-pentenal had 
a KI of 0.172 mM.  The Michaelis-Menton plot shown in Figure III. 10 is of 0.133 mM 
trans-2-hexenal, giving a KI of 0.0196 mM.  The Michaelis-Menton plot of trans-2-
octenal at a concentration of 0.075 mM is depicted in Figure III. 11. with a KI of 0.0278 
mM. Figure III.12 shows the Michaelis-Menton plot for 0.186 mM trans-2-nonenal with 
a KI of 0.0327 mM.  
Table III. 1 shows the Vmax and Vmax app for the aldehydes being used. The 
calculated values for KM, KMapp, and KI are listed in Table III. 2 for each aldehyde. 
These values were calculated according to Equations II.1 and II.2.  The rate at which  
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CYP2A6 is at ½ it’s maximum velocity, KM, were consistent at a concentration of 
substrate around the 2 to 3 µM range (Table III. 2).   
Based on the chain length, the more potent inhibitors were trans-2-hexenal, trans-
2-octenal, which gave KI values near 0.02 mM. These results are fully consistent with 
these obtained in the initial screening experiments. The Vmax and Vmax app reached 
approximately the same value, leading to the assumption that all of the unsaturated 
aldehydes listed are competitive inhibitors.   
As the straight chain unsaturated aldehydes deviate away from a 6-8 carbon hain 
length, the inhibition dramatically decreases.  The ability of these compounds to inhibit 
CYP2A6 shows that the hypothesis was correct about the need for an α,β u saturated 
bond, as well as the need for a smaller compound with about seven or eight carbons long. 
Again the experimental data support an active site structure that is highly constrained and 
binds to substrates via π-stacking interactions. 
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Figure III. 8: Plot of area vs. coumarin concentration in the presence (red) and absence 
(green) of crotonaldehyde (0.557 mM). Reactions contained inhibitor, human liver 
microsomes, a range of substrate concentrations from 0 µM to 20 µM, and 1 mM 
NADPH. 
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Figure III. 9: Plot of area vs. coumarin concentration in the presence (red) and absence 
(green) of trans-2-pentenal (0.464 mM).  Reactions contained inhibitor, human liver 
microsomes, a range of substrate concentrations from 0 µM to 20 µM, and 1 mM 
NADPH. 
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Figure III. 10: Plot of area vs. coumarin concentration in the presence (red) and absence 
(green) of trans-2-hexenal (0.133 mM). Reactions contained inhibitor, human liver 
microsomes, a range of substrate concentrations from 0 µM to 20 µM, and 1 mM 
NADPH. 
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Figure III. 11: Plot of area vs. coumarin concentration in the presence (red) and absence 
(green) of trans-2-octenal (0.0754 mM). Reactions contained inhibitor, human liver 
microsomes, a range of substrate concentrations from 0 µM to 20 µM, and 1 mM 
NADPH. 
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Figure III. 12: Plot of area vs. coumarin concentration in the presence (red) and absence 
(green) of trans-2-nonenal (0.125 mM).  Reactions contained inhibitor, human liver 
microsomes, a range of substrate concentrations from 0 µM to 20 µM, and 1 mM 
NADPH. 
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 Table III. 1: Values of Vmax and Vmax app. from the Michaelis-Menton Plots for each 
aldehyde.  
 
Aldehyde Vmax Vmax app 
Crotonaldehyde 44300 30600 
Trans-2-pentenal 65300 61600 
Trans-2-hexenal 54700 53900 
Trans-2-octenal 68200 55100 
Trans-2-nonenal 22500 13200 
Trans-Cinnamaldehyde 15800 16400 
 
 
 
Table III. 2: Calculated values for KI, KM, KM app for each unsaturated aldehyde as listed. 
  
Aldehyde Km app  (µM) Km (µM) Ki (mM) 
Crotonaldehyde 2.71 2.08 0.205 
Trans-2-pentenal 12.4 3.36 0.171 
Trans-2-hexenal 26.8 3.45 0.0196 
Trans-2-octenal 10.4 2.81 0.0278 
Trans-2-nonenal 13.3 1.99 0.0327 
Trans-Cinnamaldehyde 5.37 1.4 0.0214 
III. B. Inductions of Phase II Drug Metabolizing Enzymes by Essential Oils and      
Aldehydes 
 
 To probe the effects of essential oil of cassia on phase II gene induction, HepG2 
liver cells were grown in culture and treated with the obtained pure essential oil 
(determined by GC/MS by Birch Hill Happenings) from Birch Hill Happenings. Cells 
were grown according to the procedure described in the experimental section and RNA 
and cDNA was prepared for analysis of gene expression. Initially we tested β-actin as a 
control, and conditions were established for consistent amplification of a portion of these 
genes using RT-PCR. Once the RNA of the HepG2 cells was induced and isolated, 
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converted into DNA and amplified via RT-PCR, the expression levels were analyzed 
with gel electrophoresis.  
III. B. i. RT-PCR Internal Controls: β-actin and GAPDH 
The results for the internal controls, β-actin and GAPDH, in the preliminary 
experiment with cassia oil, is shown in Figure III. 13. The figure shows results of RT-
PCR of these genes following the procedure described previously with annealing 
temperatures of 56oC and 57.5oC for β-actin and GAPDH, respectively. β-actin and 
GAPDH had consistent bands when increasing the concentration of cassia oil, as 
expected. Figure III. 13 showed the expression of β-actin for the preliminary 
experiments, having the correct sized fragments of 285 bp. Lanes 1 and 2 contained 
control cDNA, in which the cells did not have any essential oil of cassia added to them. 
Lane 3 samples had 10 µg/mL of cassia oil added to the cells. Lane 4 samples contained 
20 µg/mL cassia oil, and lane 5 contained 100 µg/mL cassia oil. The expression of this 
was constant and was expected to be constant as β-actin is considered a “housekeeping” 
gene and one that is not inducible.   
Figure III. 13 show the expression levels of GAPDH, which is another internal 
control. The bands showed that the samples contained consistent amounts of cDNA and 
at the correct size of 258 bp. Lanes 1 and 2 contained control cDNA, in which the cells 
did not have any cassia essential oil added to them. Lane 3 samples had 10 µg/mL of 
cassia oil added to the cells. Lane 4 samples contained 20 µg/mL cassia oil, and lane 5 
contained 100 µg/mL cassia oil. These were also expected to be constant. 
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III. B. ii. RT-PCR Analysis of EPHX1 
 RT-PCR of the EPHX1 gene was also carried out, following the procedure 
described previously with an annealing temperatures of 60oC.  Figure III. 13 shows the 
expression of EPHX for the preliminary experiments, having the correct sized fragments 
of 273 bp. Lanes 1 and 2 contain control cDNA, in which the cells did not have any 
cassia oil added to them. Lane 3 samples had 10 µg/mL of cassia oil added to the cells. 
Lane 4 samples contained 20 µg/mL cassia oil, and lane 5 contained 100 µg/mL cassia 
oil. The gel shows an increase in the expression of the EPHX1 when increasing the 
concentration of cassia oil. 
III. B. iii. RT-PCR Analysis of HNMT 
 RT-PCR of the HNMT gene, following the procedure described previously with 
annealing temperatures of 60oC.  Figure III. 13 shows the amplified cDNA from HepG2 
cells treated with cassia oil for the HNMT gene. From the Figure it can be seen that a 
PCR product was formed having the correct size of 219 bp. Lanes 1 and 2 contain control 
cDNA, in which the cells did not have any cassia oil added to them. Lane 3 samples had 
10 µg/mL of cassia oil added to the cells. Lane 4 samples contained 20 µg/mL cassia oil, 
and lane 5 contained 100 µg/mL cassia oil. The gel shows an increase in the amplified 
DNA for the HNMT gene with increasing concentration of cassia oil.  In particular, the 
increase appears to be most noticeable using the two highest doses of cassia oil, 20 
µg/mL and 100 µg/mL. 
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III. B. iv. RT-PCR Analysis of HAT1 
 RT-PCR of the HAT1 gene, following the procedure described previously with 
annealing temperatures of 62oC.  The induction of the HAT1 gene is shown in F gure 
III. 13 for the preliminary experiments, where a band having the correct size of 215 bp, 
was observed. Lanes 1 and 2 contain control cDNA, in which the cells did not have any 
cassia oil added to them. Lane 3 samples had 10 µg/mL of cassia oil added to the cells. 
Lane 4 samples contained 20 µg/mL cassia oil, and lane 5 contained 100 µg/mL cassia 
oil. The gel shows inconclusive evidence for the induction of the HAT1 gene when 
increasing the concentration of cassia oil. For example, in lane 3 there appars to be no 
increase in band intensity, whereas lane 4 does have an increase. At the highest dose, 
however it appears to drop back to a lower intensity. 
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GAPDH
EPHX1
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Figure III. 13: Gel electrophoresis of the β-actin gene showed a constant band for all of 
the samples containing, no cassia essential oil and as well as samples increa ing amounts 
of the oil from 10 µg/mL to 100 µg/mL. 
 
 
III. B. v. RT-PCR Analysis of Heme Oxygenase-1  
RT-PCR of the HO-1 gene, following the procedure described previously with 
annealing temperatures of 55oC.  Figure III. 14 shows the expression of HO-1 for the 
preliminary experiments, having the correct size of around 270 bp. Lane 1 contains 
control cDNA, in which the cells did not have any cassia oil added to them. Lane 2 
samples had 10 µg/mL of cassia oil added to the cells. Lane 3 samples contained 20 
µg/mL cassia oil, and lane 4 contained 100 µg/mL cassia oil. These samples were 
incubated for five hours at 37oC prior to RNA isolation. The gel shows a slight increase 
in the amplified DNA for the HO-1 gene with increasing concentration of cassia oil, 
Lane 1   Lane 2  Lane 3  Lane 4  Lane 5 
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when compared to β-actin levels.  In particular, the increase appears to be most noticeable 
using the two middle (lane 2 and 3) doses of cassia oil, 10 µg/mL and 20 µg/mL. There 
was a decrease in lane 4 which contained the highest concentration of Cassia oil, 100 
µg/mL, suggesting possibly that the cells may be under-expressing this gene or perhaps 
even being killed. 
Figure III. 15 shows the expression of HO-1 for the preliminary experiments, 
having the correct size of around 270 bp. Lane 1 contains control cDNA, in which the 
cells contained 20 µg/mL cassia oil and were immediately harvested for RNA isolation. 
Lane 2 samples had 20 µg/mL of cassia oil added and bathed at 37oC for 1 hour. Lane 3 
samples contained 20 µg/mL cassia oil added and bathed at 37oC for 5 hours. Lane 4 
contained 20 µg/mL cassia oil added and bathed at 37oC for 24 hours. The gel shows an 
increase in the amplified DNA for the HO-1 gene when compared to β-actin expression.  
In particular, the increase appears to be most noticeable using a 5 hour incubation of 
cassia oil (lane 3). After 24 hours of incubation the induction decreased possibly pointing 
to the oxidation of the aldehyde by aldehyde dehydrogenase. 
Figure III. 16 shows the expression of HO-1 for the preliminary experiments in 
the presence of cinnamaldehyde, having the correct size of around 270 bp. Lane 1 
contains control cDNA, in which the cells did not have any cinnamaldehyde added to 
them. Lane 2 samples had 10 µg/mL of cinnamaldehyde added to the cells. Lane 3 
samples contained 20 µg/mL cinnamaldehyde, and lane 4 contained 100 µg/mL 
cinnamaldehyde. These samples were incubated for five hours at 37oC prior to RNA 
isolation. The gel shows a slight increase in the amplified DNA for the HO-1 gene with 
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increasing concentration of cinnamaldehyde, when compared to β-actin levels.  In 
particular, the increase appears to be most noticeable using the two middle (lane 2 and 3) 
doses of cinnamaldehyde, 10 µg/mL and 20 µg/mL. However, as seen there is a slight 
drop in the intensity in the band of lane 4 containing the highest concentration of 
cinnamaldehyde (100 µg/mL), potentially due to the high increase in aldehyde 
concentration which could potentially harm the cells. This data is consistent with the 
increase in intensity of cassia oil samples in lane 2 and 3. 
Figure III. 17 shows the expression of HO-1 for the preliminary experiments in 
the presence of cinnamaldehyde, having the correct size of around 270 bp. Lane 1 
contains control cDNA, in which the cells contained 20 µg/mL cinnamaldehyde and were 
immediately harvested for RNA isolation. Lane 2 samples had 20 µg/mL of 
cinnamaldehyde added and bathed at 37oC for 1 hour. Lane 3 samples contained 20 
µg/mL cinnamaldehyde added and bathed at 37oC for 5 hours. Lane 4 contained 20 
µg/mL cinnamaldehyde added and bathed at 37oC for 24 hours. The gel shows an 
increase in the amplified DNA for the HO-1 gene when compared to β-actin expression.  
In particular, the increase appears to be most noticeable using a 5 hour incubation of 
cinnamaldehyde (lane 3). This data is consistent with the increase in intensity of cassia 
oil samples after five hours of incubation. With a 24 hour incubation the induction 
decreased pointing to the possibility of oxidation of the aldehyde. 
Cassia oil consists of around 80% trans-cinnamaldehyde and in the preliminary 
trials seemed to have good induction on HNMT, EPHX, and HO-1. Cinnamaldehyde and 
cassia were both shown to also have an induction of HepG2 gene expression of the gene  
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Heme Oxygenase 1, a known anti-oxidant, at 20 µg/mL and after a five hour incubation. 
After 24 hours of incubation the induction decreased for both cassia oil and 
cinnamaldehyde, possibly pointing to the oxidation of the aldehyde. The preliminary dat  
showing this induction of these genes is consistent with past research showing 
electrophiles are responsible for increasing induction of antioxidant genes by the Nrf2 
pathway.  
 
 
 
 
Figure III. 14: Gel Electrophoresis of the induction of the HO-1 gene in HepG2 cells, in 
the presence of increasing concentrations of cassia essential oil from 10 µg/mL to 100 
µg/mL, with a five hour incubation at 37oC. 
 
 
 
    
 
 
Figure III. 15: Gel Electrophoresis of the induction of the HO-1 gene in HepG2 cells, in 
the presence of 20 µg/mL cassia oil for 0, 1, 6, and 24 hours of incubation at 37oC. 
 
 
      Lane 1         Lane 2          Lane 3           Lane 4  
      Lane 1         Lane 2          Lane 3           Lane 4  
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Figure III. 16: Gel Electrophoresis of the induction of the HO-1 gene in HepG2 cells, in 
the presence of increasing concentrations of cinnamaldehyde from 10 µg/mL to 100 
µg/mL, with a five hour incubation at 37oC. 
 
 
 
 
Figure III. 17: Gel Electrophoresis of the induction of the HO-1 gene in HepG2 cells, in 
the presence of 20 µg/mL cinnamaldehyde for 0, 1, 6, and 24 hours of incubation at 37oC. 
 
 
      Lane 1         Lane 2          Lane 3           Lane 4  
      Lane 1         Lane 2          Lane 3           Lane 4  
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CHAPTER IV 
CONCLUSIONS 
 
 Coumarin 7-hydroxylation assay has become a valuable tool to probe the affect of 
CYP2A6 in the presence of an aldehyde. Unsaturated aldehydes have been shown to have 
inhibited CYP2A6 with KI values in the µM range. As predicted the unsaturated 
aldehydes with a carbon chain length of six to eight carbons, were strong competit rs in 
the active site against coumarin. It has been shown that trans-cinnamaldehyde was also a 
good inhibitor as well.  
These inhibition abilities of the unsaturated aldehydes are attributed to the active 
site cavity and the amino acid residues which are available for interaction with the 
substrate or inhibitor.  Due to the presence of Asn 297, and Phe 107, the unsaturated 
aldehydes were able to have π stacking interactions with Phe 107 and H-bond with Asn 
297. Whereas, saturated aldehydes lack the ability for π stacking interactions making it 
less energetically favorable to be in the active site than coumarin. This will lead to further 
research involving similar compounds that may be used for more potent inhibition of 
CYP2A6 for possible medical uses. 
Electrophiles are very well known inducers of the phase II enzymes and are 
involved in the release of Nrf2 from the Keap1/Cul3 complex. It has now been shown 
that cassia oil, containing 80% trans-cinnamaldehyde induces phase II enzymes, such as
Heme Oxygenase1, Epoxide Hydrolases and Histamine N-methyl-transferases and has 
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the potential to induce others. Cinnamaldehyde and cassia were both shown to also have 
an induction of HepG2 gene expression of the gene Heme Oxygenase 1, a known anti-
oxidant gene, at 20 µg/mL and after a five hour incubation. This will provide a starting 
point for testing this theory using other aldehydes and will lead further understanding of 
the Nrf2 pathway and the antioxidant defense system. 
Phase I and phase II enzyme regulation has been shown with these unsaturated 
aldehydes and further research with such compounds would lead to further knowledge on 
their impacts metabolism, pharmacodynamics, and drug-drug interactions that these 
compounds may have.  
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